China · Delayed Price · Currency is CNY Sinocelltech Group Company Description
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research and development and production of recombinant proteins, antibody drugs, and vaccines in China.
The company offers Anpingxi, an antibody drug and anti-tumor product; Anjiayin for the treatment of hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and SCTV01C and SCTV01E, which are mutant strain recombinant protein vaccines.
Its product pipeline includes SCT630 used for the treatment of autoimmune diseases; SCT510 for treating solid tumors; SCT-I10A, a monoclonal antibody injection, which is in phase 3 trials for the treatment of solid tumors; SCTV01 vaccine for the treatment of corona virus; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000 for the treatment of human papillomavirus, as well as SCTA01, which is in phase 2/3 clinical research trials for treating SARS COV-2.
The company was founded in 2002 and is based in Beijing, China. Sinocelltech Group Limited is a subsidiary of Lhasa Alike Investment Consulting Co., Ltd.
| Country | China |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,277 |
| CEO | Liangzhi Xie |
Contact Details
Address: No. 31, Kechuang 7th Street Beijing, 100176 China | |
| Phone | 86 10 5862 8288 |
| Website | sinocelltech.com |
Stock Details
| Ticker Symbol | 688520 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100003ZL3 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Liangzhi Xie Ph.D. | Chairman of the Board and GM |
| Jie Ma | Accounting Supervisor and Financial Director |
| Dr. Yang Wang | Deputy GM and Director |
| Fanbin Pan | Head of Engineering Equipment Department |
| Li Ming Tang | Deputy GM, Secretary of the Board and Director |